Elevation Oncology (Elevation Oncology) Pre-Tax Income : $-39.32 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Elevation Oncology's pretax income for the three months ended in Mar. 2024 was $-10.70 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-39.32 Mil. Elevation Oncology's pretax margin was %.

Elevation Oncology Pre-Tax Income Historical Data

The historical data trend for Elevation Oncology's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology Pre-Tax Income Chart

Elevation Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-17.27

-32.04

-95.06

-45.67

Elevation Oncology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial												-17.05	-10.11	-10.63	-7.89	-10.70

Competitive Comparison of Elevation Oncology's Pre-Tax Income

For the Biotechnology subindustry, Elevation Oncology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elevation Oncology's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elevation Oncology's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's Pre-Tax Income falls into.

Elevation Oncology Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Elevation Oncology's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-40.338	+	-5.036	+	-4.2	+	3.9	+	7.105427357601E-15
	=	-45.67

Elevation Oncology's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-9.869	+	-0.942	+	0	+	0	+	0.115
	=	-10.70

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.32 Mil.

Elevation Oncology (NAS:ELEV) Pre-Tax Income Explanation

Elevation Oncology's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-10.696	/	0
	=	%

Elevation Oncology Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Elevation Oncology (Elevation Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106

Website

https://www.elevationoncology.com

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Executives

Tammy Furlong	officer: CHIEF FINANCIAL OFFICER	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen	officer: Chief Medical Officer	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff	other: Managing Member	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	director, other: Managing Member	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin	director	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106